Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
-4.66% $5.32
America/New_York / 28 mar 2024 @ 13:33
FUNDAMENTALS | |
---|---|
MarketCap: | 256.46 mill |
EPS: | 0.450 |
P/E: | 11.82 |
Earnings Date: | May 01, 2024 |
SharesOutstanding: | 48.21 mill |
Avg Daily Volume: | 0.626 mill |
RATING 2024-03-28 |
---|
S- |
Strong Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Buy | |
DE: | Strong Buy | |
P/E: | Strong Buy | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 11.82 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
2.01x |
Company: PE 11.82 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.176 (-103.30%) $-5.50 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 4.69 - 5.91 ( +/- 11.58%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-15 | Auerbach Alan H | Buy | 6 577 | Common Stock |
2024-03-15 | Auerbach Alan H | Buy | 9 047 | Stock Option (Right to Buy) |
2024-02-12 | Wong Alvin F | Buy | 43 307 | Common Stock |
2024-02-12 | Wong Alvin F | Buy | 59 946 | Stock Option (Right to Buy) |
2024-02-12 | Nougues Maximo F | Buy | 43 307 | Common Stock |
INSIDER POWER |
---|
69.48 |
Last 99 transactions |
Buy: 2 879 886 | Sell: 561 464 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $5.32 (-4.66% ) |
Volume | 0.148 mill |
Avg. Vol. | 0.626 mill |
% of Avg. Vol | 23.59 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $5.36 | N/A | Active |
---|
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.